ITL Health Group (ASX:ITD), an innovative global medical technology company is pleased to announce that Melbourne based Henslow have initiated coverage on ITL Health Group.
A copy of the report is available on the ITL Health Group website site today:
https://www.itlhealthgroup.com/analyst-research/
The analysts responsible for writing the report did not receive any direct benefits from ITL Health Group. Disclosures and Analyst Certifications can be found on page 19 of the report.
Enquires
ITL Health Group
Trevor Doolan
Company Secretary
T: +61 3 8773 3050
Media & Analysts
Walbrook IR
Ben Knowles
T: +61 0 426 277 760
E: ben.knowles@walbrookir.com.au
About ITL Health Group (ASX:ITD)
ITL Health Group is an innovative global medical technology company that creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the blood culture testing market, estimated to be worth US$4.8bn by 2021.
ITL Health Group holds an IP portfolio of over 50 patents and sells into 55 countries, protecting healthcare workers in millions of procedures annually.
